Tracking adult neovascularization during ischemia and inflammation using Vegfr2-LacZ reporter mice

Journal of Vascular Research

Volumn 45, Issue 5, 2008, Pages 437-444

  Heidenreich, Regina ^a,c,g   Murayama, Toshinori ^c,d   Silver, Marcy ^c   Essl, Christine ^a   Asahara, Takayuki ^c,e,f   Röcken, Martin ^a   Breier, Georg ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

^e RIKEN   (Japan)

^f TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Adult neovascularization; Inflammation; Ischemia; Vascular endothelial growth factor receptor 2

Indexed keywords

BETA GALACTOSIDASE; CD31 ANTIGEN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA; ENHANCER REGION; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIMB ISCHEMIA; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PUNCH BIOPSY; REPORTER GENE; SKIN BIOPSY; TRANSGENIC MOUSE; WOUND HEALING; ANIMAL; CORNEA NEOVASCULARIZATION; DISEASE MODEL; GENETICS; ISCHEMIA; LACTOSE OPERON; METABOLISM; PATHOPHYSIOLOGY; SKELETAL MUSCLE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENHANCER ELEMENTS (GENETICS); GENES, REPORTER; INFLAMMATION; ISCHEMIA; LAC OPERON; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS (GENETICS); VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; WOUND HEALING;

EID: 50349085253     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000126106     Document Type: Article

References (41)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
3. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
4. Gillitzer R, Goebeler M: Chemokines in cutaneous wound healing. J Leukoc Biol 2001;69:513-521.
5. Brown LF, et al: Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J Immunol 1995;154:2801-2807.
6. Lange-Asschenfeldt B, et al: Increased and prolonged inflammation and angiogenesis in delayed-type hypersensitivity reactions elicited in the skin of thrombospondin-2-deficient mice. Blood 2002;99:538-545.
7. Creamer JD, Barker JN: Vascular proliferation and angiogenic factors in psoriasis. Clin Exp Dermatol 1995;20:6-9.
8. Szekanecz Z, Szegedi G, Koch AE: Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Invest Med 1998;46:27-41.
9. Carmeliet P: Angiogenesis in health and disease. Nat Med 2003,9:653-660.
10. Rajashekhar G, et al: Continuous endothelial cell activation increases angiogenesis: evidence for the direct role of endothelium linking angiogenesis and inflammation. J Vasc Res 2006;43:193-204.
11. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
12. Millauer B, et al: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-579.
13. Millauer B, et al: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996;56:1615-1620.
14. Heidenreich R, et al: Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. Int J Cancer 2004;111:348-357.
15. Xia YP, et al: Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003;102:161-168.
16. O'Reilly MS, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
17. Yokoyama Y, et al: Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res 2000;60:4362-4365.
18. Izumi Y, et al: Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts. Cancer Res 2003;63:747-751.
19. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 2005;438:932-936.
20. Ferrara N: VEGF as a therapeutic target in cancer. Oncology 2005;69(suppl 3):11-16.
21. Isner JM, et al: Clinical evidence of angiogenesis after arterial gene transfer of ph-VEGF165 in patient with ischaemic limb. Lancet 1996;348:370-374.
22. Baumgartner I, et al: Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-1123.
23. Luttun A, et al: Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-840.
24. Shyu KG, et al: Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 2003;114:85-92.
25. Makinen K, et al: Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002;6:127-133.
26. Henry TD, et al: The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-1365.
27. Kappel A, et al: Identification of vascular endothelial growth factor (VEGF) receptor 2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 1999;93:4284-4292.
28. Heidenreich R, Kappel A, Breier G: Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk-1) promoter/enhancer sequences. Cancer Res 2000;60:6142-6147.
29. Kappel A, et al: Role of SCL/Tal-1, GATA, and ets transcription factor binding sites for the regulation of flk-1 expression during murine vascular development. Blood 2000;96:3078-3085.
30. Elvert G, et al: Cooperative interaction of hypoxia inducible factor (HIF)-2α and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 2003;278:7520-7530.
31. Couffinhal T, et al: Mouse model of angiogenesis. Am J Pathol 1998;152:1667-1679.
32. Muthukkaruppan V, Auerbach R: Angiogenesis in the mouse cornea. Science 1979;205:1416-1418.
33. Schlaeger TM, et al: Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA 1997;94:3058-3063.
34. Leppink DM, et al: Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration. Transplantation 1989;48:874-877.
35. Hallmann R, et al: Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev Dyn 1995;202:325-332.
36. Miotla J, et al: Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000;80:1195-1205.
37. De Bandt M, et al: Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol 2003;171:4853-4859.
38. Millauer B, et al: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-846.
39. Zhang N, et al: Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood 2004;103:617-626.
40. Galeano M, et al: Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetologia 2003;46:546-555.
41. Watanabe H, et al: Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity. Exp Dermatol 2004;13:671-681.